NASDAQ:TGTX News 3 November 2025 - 11 January 2026

TG Therapeutics shares fell 7% to $28.35 by late Friday, reversing early gains and hitting session lows. The drop comes ahead of CEO Michael Weiss’s scheduled presentation at the J.P. Morgan Healthcare Conference on Jan. 13. Traders are watching for updates on Briumvi demand and 2026 plans.

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseasesgurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S.gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers. Briumvi – A Breakthrough in Multiple Sclerosis Therapy Briumvi (ublituximab-xiiy) is TG’s flagship drug, approved by the FDA in December 2022 for adults with relapsing forms of multiple sclerosis (RMS)ir.tgtherapeutics.com. It